[EN] PAMOATE SALT OF MONOAMINE ANTI-PARKINSON'S AGENTS, METHOD OF PREPARATION AND USE THEREOF<br/>[FR] AGENTS ANTI-PARKINSON DE TYPE SELS DE PAMOATE DE MONOAMINE, LEUR PROCÉDÉ DE PRÉPARATION ET D'UTILISATION
申请人:GU ZI QIANG
公开号:WO2019036624A1
公开(公告)日:2019-02-21
In various embodiments, provided herein are pamoate salts of monoamine Anti-Parkinsons disease agents including rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and safinamide, pharmaceutical composition comprising the same, methods of preparing the same, and methods of using the same. For example, the pamoate salt herein can be characterized by a molar ratio of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, or safinamide to pamoic acid of about 1:1 or about 2:1. The pamoate salt herein can also be crystalline including anhydrous, hydrate or solvate forms, or their polymorphs, or amorphous. The pamoate salts described herein can provide a long acting and/or extended release profile of the monoamine agents for the treatment of Parkinsons disease (PD). Thus, also provided herein are methods of preparing a long acting and/or extended release injectable formulation of the monoamine agents using their respective pamoate salts. And in some embodiments, provided herein are methods of treating a subject in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide.
在各种实施方式中,本文提供了包括罗蒂果汀、洛匹尼罗尔、普拉米贝克索、西列吉林、拉沙吉林和萨非那米德等单胺抗帕金森病药物的帕莫酸盐,以及包括它们的制药组合物、制备方法和使用方法。例如,本文中的帕莫酸盐可以由罗蒂果汀、洛匹尼罗尔、普拉米贝克索、西列吉林、拉沙吉林或萨非那米德与帕莫酸的摩尔比约为1:1或2:1来表征。本文中的帕莫酸盐也可以是结晶的,包括无水、水合物或溶剂化合物形式,或它们的多晶形式,或无定形的。本文描述的帕莫酸盐可以为帕金森病(PD)的治疗提供长效和/或延长释放的单胺药物剂型。因此,本文还提供了使用它们各自的帕莫酸盐制备长效和/或延长释放注射剂制剂的方法。在某些实施方式中,本文还提供了治疗需要的受试者的方法,包括给予包含罗蒂果汀、洛匹尼罗尔、普拉米贝克索、西列吉林、拉沙吉林和/或萨非那米德的帕莫酸盐的制药组合物。